Clinical and epidemiological profile of Severe Acute Respiratory Syndrome suspected patients during a period of five years in the city of Juiz de Fora, MG.
Clinical and epidemiological profile in SARS
DOI:
https://doi.org/10.34019/1982-8047.2023.v49.41170Keywords:
Severe Acute Respiratory Syndrome; Clinical-epidemiological profileAbstract
Respiratory tract infections represent one of the main causes of morbidity and mortality in the world. Among the clinical presentations of viral infections, we have the Severe Acute Respiratory Syndrome (SARS), which is a flu-like illness with signs of severity, representing a notifiable condition. The objective of the study is to evaluate the occurrence of Severe Acute Respiratory Syndrome in the population of Juiz de Fora, MG, during a period of 5 years. The data analyzed were provided by the municipality's epidemiological surveillance. Clinical/epidemiological data from the notification forms between the years 2016 and 2021 were collected. A total of 20,817 patients were analyzed. The mean age between 2016 and 2019 was 24.36 years (SD± 25.7) and between 2020 and 2021 the mean was 52.17 years (SD± 24.4). Between 2016-2019, the involvement by age group was concentrated among Infants (0-2 years) 25.41% of cases, Children (3-12 years) 22.31% and Young Adults (18-39 years) 23 .45% of cases. Between 2019 and 2021 there was a change in this profile with a higher occurrence of cases concentrated among middle-aged and elderly adults. Regarding the etiology, the Influenza virus was responsible for 6.11% of the cases, 19.4% were caused by other respiratory viruses and SARS-CoV-2 in 2 years was responsible for 72.59% of the cases. Between 2019-2021, 99.41% of cases required hospitalization, with 48.01% of patients going to the ICU. Patients with Risk Factors had an Odds Ratio of 3.7 to evolve to death. COVID-19 impacted SARS, causing a change in involvement, increasing the mean age and the presence of risk factors. Other respiratory viruses besides Influenza can be the etiology of severe cases. Juiz de Fora promotes hospitalization in almost 100% of cases in the ward. In addition, about 50% of cases require ICU care.
Downloads
References
Forum of International Respiratory Societies. The global impact of respiratory disease. 2nd. edition. Sheffield: European Respiratory Society; 2017.
Santos NSO, Romanos MTV, Wigg MD. Virologia humana. Grupo Gen-Guanabara Koogan; 2015.
Ministério da Saúde (BR). Protocolo de tratamento de influenza 2017 [Internet]. Brasília: Ministério da Saúde; 2017. Disponível em: http://bvsms.saude.gov.br/bvs/publicacoes/protocolo_tratamento_influenza_2017.pdf
Klepser ME. Socioeconomic impact of seasonal (epidemic) influenza and the role of over-the-counter medicines. Drugs. 2014; 74(13):1467-79. doi: 10.1007/s40265-014-0245-1.
Rodrigues RJB, Fonseca RP. Gripe sazonal: um problema de saúde pública. Leiria: ACES Pinhal Litorial; 2015. 10.13140/RG.2.1.3054.6009.
Barreto ML. Papel da epidemiologia no desenvolvimento do Sistema Único de Saúde no Brasil: histórico, fundamentos e perspectivas. Rev Bras Epidemiol. 2002; 5:4-17. doi.org/10.1590/S1415-790X2002000400003
Dean AG, Sullivan KM, Soe MM. OpenEPI: open source epidemiologic statistcs for public health [Internet]. OpenEPI; 2013 [citado em 2023 mar. 7]. Disponível em: http://www.openepi.com/Menu/OE_Menu.htm.
Ministério da Saúde (BR). Secretaria de Vigilância em Saúde. Ficha de registro individual: casos de síndrome respiratória aguda grave hospitalizado [Internet]. [citado em 2023/03/15]. Disponível em: http://lproweb.procempa.com.br/pmpa/prefpoa/cgvs/usu_doc/ficha_sivep_gripe_srag_hospital_enviada_ves_22.05.2019.pdf.
Ministério da Saúde (BR). Secretaria de Vigilância em Saúde. Sistema de Informação da Vigilância Epidemiológica da Gripe. Ficha de registro individual: casos de síndrome respiratória aguda grave hospitalizado [Internet]. 2021 [citado em 2023/04/27]. Disponível em: https://www.saude.go.gov.br/files/vigilancia/epidemiologica/fichas-de-notificacao/SindromeRespiratoriaAgudaGrave-SIVEPGRIPE.pdf.pdf.
Dyussenbayev A. Age periods of human life. Advances in Social Sciences Research Journal. 2017; 4(6).
Elliott SP, Ray CG. Viral infections of the lower respiratory tract. Pediatric Respiratory Medicine. 2008; 481-9.
Czeisler MÉ, Marynak K, Clarke KEN, Salah Z, Shakya I et al. Delay or avoidance of medical care because of Covid-19-related concerns: United States, June 2020. MMWR Morb Mortal Wkly Rep. 2020; 69(36):1250-7. doi: 10.15585/mmwr.mm6936a4.
Lessler J, Reich NG, Brookmeyer R, Perl TM, Nelson KE, Cummings DA. Incubation periods of acute respiratory viral infections: a systematic review. Lancet Infect Dis. 2009; 9(5):291-300. doi: 10.1016/S1473-3099(09)70069-6.
Lauer SA, Grantz KH, Bi Q, Jones FK, Zheng Q et al. The incubation period of coronavirus disease 2019 (Covid-19) from publicly reported confirmed cases: estimation and application. Ann Intern Med. 2020; 172(9):577-82. doi: 10.7326/M20-0504.
Rodríguez-Martínez CE, Rodríguez DA, Nino G. Respiratory syncytial virus, adenoviruses, and mixed acute lower respiratory infections in children in a developing country. J Med Virol. 2015; 87(5):774-81. doi: 10.1002/jmv.24139.
Tabernero E, Ruiz LA, España PP, Méndez R, Serrano L et al. Covid-19 in young and middle-aged adults: predictors of poor outcome and clinical differences. Infection. 2022; 50(1):179-89. doi: 10.1007/s15010-021-01684-9.
European Centre for Diseases Prevention and Control. Weekly Covid-19 country overview [Internet]. Stockholm: ECDC; 2020 [citado em 2023 mar.]. Disponível em: https://www.ecdc.europa.eu/en/covid-19/countryoverviews.
Niccoli T, Partridge L. Ageing as a risk factor for disease. Curr Biol. 2012; 22(17):R741-52.
Ioannidis JPA, Axfors C, Contopoulos-Ioannidis DG. Population-level Covid-19 mortality risk for non-elderly individuals overall and for non-elderly individuals without underlying diseases in pandemic epicenters. Environ Res. 2020; 188:109890. doi: 10.1016/j.envres.2020.109890.
Watson A, Wilkinson TMA. Respiratory viral infections in the elderly. Ther Adv Respir Dis. 2021; 15:1753466621995050. doi: 10.1177/1753466621995050.
Ison MG. Antiviral Treatments. Clin Chest Med. 2017; 38(1):139-53. doi: 10.1016/j.ccm.2016.11.008.
McLean HQ, Belongia EA, Kieke BA, Meece JK, Fry AM. Impact of late oseltamivir treatment on influenza symptoms in the outpatient setting: results of a randomized trial. Open Forum Infect Dis. 2015; 2(3):ofv100. doi: 10.1093/ofid/ofv100.
Wang D, Hu B, Hu C, Zhu F, Liu X et al. Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China. JAMA. 2020; 323(11):1061-9. doi: 10.1001/jama.2020.1585. Erratum in: JAMA. 2021; 325(11):1113.
Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev. 2014; 2014(4):CD008965. doi: 10.1002/14651858.CD008965.pub4.
Bellei N, Carraro E, Perosa A, Watanabe A, Arruda E, Granato C. Acute respiratory infection and influenza-like illness viral etiologies in Brazilian adults. J Med Virol. 2008; 80(10):1824-7. doi: 10.1002/jmv.21295.
Milder E, Arnold JC. Human metapneumovirus and human bocavirus in children. Pediatr Res. 2009; 65(5Pt2):78R-83R. doi: 10.1203/PDR.0b013e31819db90c.
Glezen WP, Greenberg SB, Atmar RL, Piedra PA, Couch RB. Impact of respiratory virus infections on persons with chronic underlying conditions. JAMA. 2000; 283(4):499-505. doi: 10.1001/jama.283.4.499.
Vardavas CI, Mathioudakis AG, Nikitara K, Stamatelopoulos K, Georgiopoulos G et al. Prognostic factors for mortality, intensive care unit and hospital admission due to SARS-CoV-2: a systematic review and meta-analysis of cohort studies in Europe. Eur Respir Rev. 2022; 31(166):220098. doi: 10.1183/16000617.0098-2022.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Lucas de Oliveira Vasconcelos Guimarães, Marina Nogueira Henriques de Oliveira, Rebeca Ferreira Cesar Campos , Sônia Maria Almeida Rodrigues, Aripuanã Sakurada Watanabe
This work is licensed under a Creative Commons Attribution 4.0 International License.
Cessão de Primeira Publicação à HU Revista
Os autores mantém todos os direitos autorais sobre a publicação, sem restrições, e concedem à HU Revista o direito de primeira publicação, com o trabalho licenciado sob a Licença Creative Commons Attribution que permite o compartilhamento irrestrito do trabalho, com reconhecimento da autoria e crédito pela citação de publicação inicial nesta revista, referenciando inclusive seu DOI.
